Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) shot up 5.3% during mid-day trading on Monday . The stock traded as high as $48.69 and last traded at $47.97, with a volume of 515,791 shares trading hands. The stock had previously closed at $45.55.

Several equities analysts recently weighed in on FPRX shares. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. Jefferies Group restated a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. Leerink Swann restated a “buy” rating and set a $45.00 target price on shares of Five Prime Therapeutics in a report on Friday, July 15th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $48.00 target price on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $52.33.

The company has a 50-day moving average price of $46.78 and a 200 day moving average price of $41.47. The stock has a market cap of $1.30 billion and a PE ratio of 5.43.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The firm earned $9.23 million during the quarter, compared to analysts’ expectations of $6.38 million. During the same quarter last year, the company posted ($0.45) EPS. The firm’s revenue was up 46.1% compared to the same quarter last year. Equities research analysts expect that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current fiscal year.

In related news, Director Peder Jensen sold 12,195 shares of the company’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total value of $603,652.50. Following the completion of the sale, the director now owns 12,195 shares in the company, valued at approximately $603,652.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Ringo sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the sale, the director now owns 500 shares of the company’s stock, valued at approximately $25,385. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Five Prime Therapeutics stock. RS Investment Management Co. LLC purchased a new stake in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 511,170 shares of the company’s stock, valued at approximately $21,214,000. RS Investment Management Co. LLC owned about 1.86% of Five Prime Therapeutics as of its most recent filing with the SEC.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.